These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 15848568

  • 1. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T, Sato S, Koyama I, Nanmoku K, Sekijima M, Tonsyo M, Kai K, Kato Y, Urashima Y, Nakajima I, Fuchinoue S, Teraoka S.
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [Abstract] [Full Text] [Related]

  • 2. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB.
    Transplantation; 2008 Nov 15; 86(9):1241-8. PubMed ID: 19005406
    [Abstract] [Full Text] [Related]

  • 4. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D, Kotnik V, Kandus A.
    Transplant Proc; 2005 Dec 15; 37(10):4230-4. PubMed ID: 16387086
    [Abstract] [Full Text] [Related]

  • 5. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A.
    Am J Transplant; 2003 Mar 15; 3(3):306-11. PubMed ID: 12614286
    [Abstract] [Full Text] [Related]

  • 6. Results of kidney transplantation in patients receiving MMF- or MMF and basiliximab-containing immunosuppression.
    Tojimbara T, Nakajima I, Sato S, Nakamura M, Kawase T, Kai K, Tsuda S, Kudo S, Fuchinoue S, Teraoka S.
    Transplant Proc; 2004 Sep 15; 36(7):2087-9. PubMed ID: 15518755
    [Abstract] [Full Text] [Related]

  • 7. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
    Teraoka S, Sato S, Sekijima M, Iwado K, Urashima Y, Kudo S, Kai K, Koyama I, Tojinbara T, Nakajima I, Fuchinoue S.
    Transplant Proc; 2005 Mar 15; 37(2):791-4. PubMed ID: 15848533
    [Abstract] [Full Text] [Related]

  • 8. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.
    Pediatr Transplant; 2005 Feb 27; 9(1):80-3. PubMed ID: 15667617
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation.
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Neylan J, Roza A, Somberg K.
    Transplant Proc; 2001 Feb 27; 33(1-2):1011-2. PubMed ID: 11267168
    [No Abstract] [Full Text] [Related]

  • 14. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M, Ming A, Zhao M.
    Clin Transplant; 2006 Feb 27; 20(3):325-9. PubMed ID: 16824149
    [Abstract] [Full Text] [Related]

  • 15. Induction with basiliximab in renal transplantation.
    Ferrer F, Machado S, Alves R, Macário F, Bastos C, Roseiro A, Mota A.
    Transplant Proc; 2010 Mar 27; 42(2):467-70. PubMed ID: 20304166
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, Fischer W, Neumayer HH, Glander P.
    Clin Nephrol; 2007 Mar 27; 67(3):164-75. PubMed ID: 17390741
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients.
    Cibrik D, Meier-Kriesche HU, Bresnahan B, Wu YM, Klintmalm G, Kew CE, Kuo PC, Whelchel J, Cohen D, Baliga P, Akalin E, Benedetti E, Wright F, Lieberman B, Ulbricht B, Jensik S, Myfortic-US01 Renal Transplant Study Group.
    Clin Transplant; 2007 Mar 27; 21(2):192-201. PubMed ID: 17425744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.